Literature DB >> 7905793

Co-stimulation with anti-CD28 (Kolt-2) enhances DNA synthesis by defective T cells in common variable immunodeficiency.

M E North1, A N Akbar, N Borthwick, K Sagawa, M Funauchi, A D Webster, J Farrant.   

Abstract

In normal T cells, an anti-CD28 MoAb (Kolt-2) will synergize with the mitogenic stimuli phytohaemagglutinin (PHA), anti-CD3 (OKT3) or a combination of anti-CD2 antibodies (OKT11 and GT2) in the induction of DNA synthesis. A subgroup of patients with common variable immunodeficiency (CVID) show a defect in DNA synthesis by T cells stimulated in vitro with the above mitogens. We have now investigated whether anti-CD28 will correct the defect. This strategy partially restored DNA synthesis, providing evidence that the CD28 co-stimulatory pathway in CVID T cells is normal. Ligation of CD28 acts through co-stimulating IL-2 secretion. The natural ligand (B7) for CD28 on antigen-presenting cells from CVID patients is expressed normally. We conclude that the defect in CVID T cells lies in pathways that lead to transcription of the IL-2 gene other than that induced by ligation of CD28 with Kolt-2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905793      PMCID: PMC1534925          DOI: 10.1111/j.1365-2249.1994.tb06511.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Clinical and immunologic analyses of 103 patients with common variable immunodeficiency.

Authors:  C Cunningham-Rundles
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

2.  A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes.

Authors:  P J Martin; J A Ledbetter; Y Morishita; C H June; P G Beatty; J A Hansen
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

3.  Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells.

Authors:  J A Ledbetter; P J Martin; C E Spooner; D Wofsy; T T Tsu; P G Beatty; P Gladstone
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

Review 4.  The role of the CD28 receptor during T cell responses to antigen.

Authors:  P S Linsley; J A Ledbetter
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

5.  A 45-kDa human T-cell membrane glycoprotein functions in the regulation of cell proliferative responses.

Authors:  H Gmünder; W Lesslauer
Journal:  Eur J Biochem       Date:  1984-07-02

6.  Relationship between IL 2 synthesis and the proliferative response to PHA in different primary immunodeficiencies.

Authors:  M López-Botet; G Fontán; M C Garcia Rodriguez; M O de Landázuri
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

7.  T-cell activation defect in common variable immunodeficiency: restoration by phorbol myristate acetate (PMA) or allogeneic macrophages.

Authors:  W Fiedler; K W Sykora; K Welte; J E Kolitz; C Cunningham-Rundles; K Holloway; G A Miller; L Souza; R Mertelsmann
Journal:  Clin Immunol Immunopathol       Date:  1987-08

8.  Functional expression of CD28 on T cell antigen receptor gamma/delta-bearing T lymphocytes.

Authors:  R Testi; L L Lanier
Journal:  Eur J Immunol       Date:  1989-01       Impact factor: 5.532

9.  Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency.

Authors:  G Kruger; K Welte; N Ciobanu; C Cunningham-Rundles; P Ralph; S Venuta; S Feldman; B Koziner; C Y Wang; M A Moore
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

10.  Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies.

Authors:  R A Van Lier; M Brouwer; L A Aarden
Journal:  Eur J Immunol       Date:  1988-01       Impact factor: 5.532

View more
  12 in total

1.  Enhanced apoptosis of T cells in common variable immunodeficiency (CVID): role of defective CD28 co-stimulation.

Authors:  M Di Renzo; Z Zhou; I George; K Becker; C Cunningham-Rundles
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

Review 2.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Common variable immune deficiency: reviews, continued puzzles, and a new registry.

Authors:  Charlotte Cunningham-Rundles; Adina Kay Knight
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  Common variable immunodeficiency: does life begin at 40?

Authors:  P Lane
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

5.  Factors that influence activated CD8+ T-cell apoptosis in patients with acute herpesvirus infections: loss of costimulatory molecules CD28, CD5 and CD6 but relative maintenance of Bax and Bcl-X expression.

Authors:  N J Borthwick; M Bofill; I Hassan; P Panayiotidis; G Janossy; M Salmon; A N Akbar
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

6.  In vivo modulation of cytokine synthesis by intravenous immunoglobulin.

Authors:  W A Sewell; M E North; R Cambronero; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

7.  Primary defect in CD8+ lymphocytes in the antibody deficiency disease (common variable immunodeficiency): abnormalities in intracellular production of interferon-gamma (IFN-gamma) in CD28+ ('cytotoxic') and CD28- ('suppressor') CD8+ subsets.

Authors:  M E North; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

8.  B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/fas), diminished CD38 expression, and undergo enhanced apoptosis.

Authors:  A Saxon; B Keld; D Diaz-Sanchez; B C Guo; N Sidell
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

9.  A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID).

Authors:  J A Rump; A Jahreis; M Schlesier; S Stecher; H H Peter
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

10.  Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients.

Authors:  V Thon; H M Wolf; M Sasgary; J Litzman; A Samstag; I Hauber; J Lokaj; M M Eibl
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.